- Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's Disease and Discovery Expertise
- Abbisko Therapeutics Is Eligible to Receive Research, Development and Commercial Milestone Payments
18 January 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter),a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the “Agreement”) with Eli Lilly and Company (“Lilly”) for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs.
Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform. Lilly will join the effort by providing prior discovery information associated with this target as well as certain additional disease knowledge and expertise.If Abbisko Therapeutics is successful in advancing the compounds to the agreed upon endpoints,Lilly will have the right to further develop and commercialize the opportunity. If Lilly elects not to advance the compounds, Abbisko Therapeutics will then have the right to further develop and commercialize. The Agreement will allow each party the opportunity to fully leverage both parties’existing compounds, platform and technologies related to the target globally to maximize patient treatment choice.
“During the past five years, Abbisko Therapeutics has established a world-class discovery engine with a proprietary platform that has delivered ten drug candidates including four already in clinical trials,” said Dr. Yao-Chang Xu, CEO of Abbisko Therapeutics.
“We are excited to leverage this platform to collaborate with Lilly on this truly novel R&D collaboration to develop innovative medicines against a critical drug target. This collaboration could significantly expand our pipeline and strengthen our capabilities as we strive to bring novel therapies to patients and their families.”
Abbisko Therapeutics is eligible to receive up to US$258 million in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties on sales resulting from the Agreement if Lilly is responsible for clinical development and commercialization.
If Abbisko Therapeutics is responsible for clinical development and commercialization, then Lilly would receive development and commercial milestone payments, as well as tiered royalties on sales resulting from the Agreement.
About Abbisko Therapeutics
Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and around the world. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built up an extensive pipeline of 14 innovative small molecule programs focused on precision oncology and immuno- oncology, including six clinical stage assets and eight pre-clinical stage assets. As of today, Abbisko Therapeutics has received ten IND or clinical trial approvals in four countries and regions.
Please visit www.abbisko.com for more information.
Source: Abbisko Therapeutics
Related News: